Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine (SHIM)
The goal of this pragmatic, quasi-experimental cluster trial is to evaluate whether simplified, onsite hepatitis C virus (HCV) treatment integrated into opioid agonist maintenance therapy (OAMT) clinics improves cure rates compared with referral-based care in Ukraine . The study includes adults (18 years and older) receiving OAMT with confirmed chronic HCV infection and no prior HCV treatment.
The main questions it aims to answer are:
- Does onsite Simplified HCV Integrated Management (SHIM) increase the proportion of patients achieving sustained virologic response 12 weeks after treatment completion (SVR12) compared with case management and referral (CMR) to specialist clinics?
- Does adding provider pay-for-performance (P4P) incentives to SHIM further improve progression along the HCV treatment cascade and SVR12 rates?
Researchers compared three models of care across 13 OAMT clinics in 12 Ukrainian cities:
- Case Management and Referral (CMR): structured referral to off-site specialist clinics for HCV treatment
- SHIM: simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
- SHIM + P4P: SHIM with provider incentives linked to completion of key cascade milestones All SHIM clinics were supported by Project ECHO telementoring to strengthen clinician capacity . The study used nationally procured direct-acting antivirals (DAAs) under routine program conditions and did not reimburse diagnostic costs.
Between February 2023 and December 2024, 616 eligible patients were enrolled .
Participants:
- Completed confirmatory HCV RNA testing
- Underwent simplified pretreatment clinical and laboratory assessment
- Received 12 weeks of pan-genotypic DAA treatment either onsite (SHIM arms) or at specialist clinics (CMR arm)
- Attended follow-up visits during treatment for adherence assessment and counseling
- Were prescribed HCV RNA testing 12 weeks after treatment completion to confirm cure (SVR12) The primary outcome was SVR12. Secondary outcomes included completion of pretreatment evaluation, treatment initiation, treatment completion, and completion of SVR assessment.
This study evaluates HCV care under real-world conditions during ongoing national treatment scale-up in Ukraine. The findings inform whether integrating simplified HCV treatment into OAMT clinics-and aligning provider incentives-can improve cure rates and accelerate progress toward HCV elimination in high-burden populations.
研究概览
地位
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Kyiv、乌克兰、01054
- Ukrainian Institute on Public Health Policy
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- currently receiving treatment at the selected OAT site (implying a diagnosis of opioid dependence according to ICD 10);
- aged 18 years or older;
- residing within the study catchment area; and
- having a positive HCV antibody test documented in the medical chart
Exclusion Criteria:
- previous HCV treatment history;
- active tuberculosis (assessed using 4-item screening questionnaire and confirmed according to the current national protocol);
- pregnant or planning pregnancy in the next 6 months;
- planning to move to another city in the next 6 months;
- unwillingness to undergo confirmatory HCV RNA PCR test at their own expense and treat HCV
学习计划
研究是如何设计的?
设计细节
- 主要用途:卫生服务研究
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Case Management and Referral
structured referral to off-site specialist clinics for HCV treatment
|
structured referral to off-site specialist clinics for HCV treatment
|
|
实验性的:Simplified HCV Integrated Management
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
|
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
|
|
实验性的:Simplified HCV Integrated Management + Pay-for-performance
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians with provider incentives linked to completion of key cascade milestones
|
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
provider incentives linked to completion of key cascade milestones
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sustained virologic response
大体时间:Up to 24 weeks after treatment completion
|
Number of participants who have HCV RNA below the limit of quantitation (≤50 IU/mL) based on clinical records
|
Up to 24 weeks after treatment completion
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Completion of all pretreatment diagnostic assessments
大体时间:Through study completion, an average of 2 weeks after baseline
|
Number of participants who complete all pretreatment diagnostic assessments according to the SHIM algorithm (complete blood count, basic metabolic panel (including creatinine), hepatic function panel, fibrosis assessment, and HBsAg testing) based on clinical records
|
Through study completion, an average of 2 weeks after baseline
|
|
Treatment initiation
大体时间:Through study completion, an average of 4 weeks after baseline
|
Number of participants who are prescribed treatment for HCV infection based on clinical records
|
Through study completion, an average of 4 weeks after baseline
|
|
Treatment completion
大体时间:Through study completion, an average of 14 weeks after baseline
|
Number of participants who complete the full course of HCV treatment as prescribed based on clinical records
|
Through study completion, an average of 14 weeks after baseline
|
|
SVR assessment completion
大体时间:Up to 24 weeks after treatment completion
|
Number of participants who complete HCV RNA testing for SVR confirmation based on clinical records
|
Up to 24 weeks after treatment completion
|
|
HCV reinfection
大体时间:12 months after treatment completion
|
Number of participants who receive a positive result of HCV RNA test at 12 months after treatment completion, based on clinical records
|
12 months after treatment completion
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 127-2022
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.